AVITA Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AVITA Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.61M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $64.25M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $50.14M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $34.42M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $13.96M | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | $10.30M | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | $8.77M | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | $5.10M | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | $5.06M | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | $3.88M | Aug 26, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.82M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $55.16M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $42.36M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $28.38M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $12.05M | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | $8.25M | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | $6.62M | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | $4.28M | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | $4.13M | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | $3.00M | Aug 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.59M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($61.85M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($35.38M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($26.67M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($14.43M) | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | ($4.72M) | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | ($6.00M) | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | ($5.64M) | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | ($10.23M) | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | ($12.91M) | Aug 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.53M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($56.59M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($42.66M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($27.51M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($14.42M) | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | ($4.70M) | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | ($5.99M) | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | ($5.63M) | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | ($10.21M) | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | ($13.02M) | Aug 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.84M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $20.36M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.82M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.86M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $7.59M | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | $3.97M | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | $4.11M | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | $3.36M | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | $3.37M | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | $2.54M | Aug 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.20M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($48.94M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($38.01M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($19.09M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($5.50M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | ($25.90M) | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | ($22.75M) | Aug 26, 2021 |
| FY2021 | Jun 30, 2019 | ($19.25M) | Aug 26, 2021 |
| FY2020 | Jun 30, 2018 | ($12.96M) | Aug 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.17M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.38M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $452.0K | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $65.0K | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $894.0K | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | $590.0K | Aug 26, 2021 |
| FY2021 | Jun 30, 2019 | $1.02M | Aug 26, 2021 |
| FY2020 | Jun 30, 2018 | $365.0K | Aug 27, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.39M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $79.71M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $111.64M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $98.26M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $116.02M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $125.50M | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | $82.46M | Aug 26, 2021 |
| FY2020 | Jun 30, 2019 | $25.78M | Aug 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.04M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $74.97M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $61.89M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $12.97M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $11.39M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $9.85M | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | $10.06M | Aug 26, 2021 |
| FY2020 | Jun 30, 2019 | $4.95M | Aug 27, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.65M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $49.06M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $84.74M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $104.62M | Feb 22, 2024 |
| FY2022 | Jun 30, 2021 | $115.66M | Feb 23, 2023 |
| FY2022 | Jun 30, 2020 | $72.40M | Feb 23, 2023 |
| FY2021 | Jun 30, 2019 | $20.83M | Aug 26, 2021 |
| FY2021 | Jun 30, 2018 | $14.03M | Aug 26, 2021 |
| FY2020 | Jun 30, 2017 | $3.93M | Aug 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($408.40M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($359.81M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($297.97M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($262.59M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($235.92M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | ($221.50M) | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | ($194.91M) | Aug 26, 2021 |
| FY2020 | Jun 30, 2019 | ($152.83M) | Aug 27, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.24M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $14.05M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $22.12M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $18.16M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $55.51M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $110.75M | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | $73.64M | Aug 26, 2021 |
| FY2020 | Jun 30, 2019 | $20.17M | Aug 27, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | 0 | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Aug 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2021 | Jun 30, 2021 | 0 | Aug 26, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Aug 26, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Aug 26, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Aug 26, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Aug 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.57M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 26.35M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 25.68M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 25.21M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 24.93M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | 24.90M | Feb 23, 2023 |
| FY2021 | Jun 30, 2020 | 21.47M | Aug 26, 2021 |
| FY2020 | Jun 30, 2019 | 18.71M | Aug 27, 2020 |